Clorox reports Q3 fiscal 2026 results tonight — and the setup heading in is notably more bearish than it was a month ago.
Short sellers have rebuilt positions sharply. SI as a percentage of the free float climbed to roughly 7.4% by April 28, up from around 6.1% at the start of the month. The week-on-week increase was 15% — a brisk acceleration that stands out against a backdrop of broadly flat positioning in the household products peer group. Days to cover from the latest FINRA data are at 4.04, giving shorts a meaningful cushion of time to unwind.
The lending market is comfortable for bears. Cost to borrow is barely 0.49%, a level that makes shorting Clorox essentially free to carry. Availability remains ample — the borrow pool is far from tight, with no squeeze pressure evident. Options tell a slightly more defensive story, but only at the margin. The put/call ratio edged up to 0.83 by the close of the week, above its 20-day average of 0.79, though the z-score of 0.51 keeps it well within normal range. The PCR did hit a 52-week high of 0.94 earlier in the week before pulling back — a brief spike that hinted at hedging demand before earnings, without the sustained pressure that would mark a structurally cautious position.
The Street's direction has been unanimous — and uniformly negative. Every analyst action in the past three weeks has been a target cut. JP Morgan's move on April 17 was the most pointed: a downgrade to Underweight with a $99 target (from Neutral at $117), marking the first outright bearish call among the recent wave and landing the new target barely above the current price. Morgan Stanley held Equal-Weight but slashed to $110 from $136 on April 23. Jefferies kept its Buy rating but trimmed to $139 from $151 — the only broadly constructive voice, though its target implies roughly 44% upside from current levels. The consensus mean target is $115.47, versus a close of $96.60. On valuation, the stock trades at a PE of 15.8x — down about 5.5% over the past month — and an EV/EBITDA of 10.6x, also compressing. Factor scores offer little offset: forward EPS growth ranks in just the 11th percentile of the universe, and EPS momentum over 30 days sits at the 35th percentile. The one standout is the dividend score, which ranks in the 100th percentile — a reminder that Clorox's yield story is intact even as the growth narrative weakens.
Institutional flows offer a small contrast to the bearish macro. Van Eck added 426,000 shares in the most recent quarter to reach 2.59% of shares outstanding. Invesco also added significantly. Passive anchors Vanguard and BlackRock added modestly. These flows look like routine rebalancing rather than conviction buying, but they do suggest the stock is not being actively abandoned at the institutional level. Insider activity over the past 90 days is negligible — a handful of small routine sales, the largest being the CFO's $25,000 disposal in April — and adds nothing to the directional story.
Looking at recent earnings reactions, the pattern is constructive on paper. The last print in February produced a one-day gain of nearly 4% and a five-day gain of over 7%. The prior release delivered a one-day move of 3.3% and a five-day gain of almost 9%. Both suggest the market has rewarded Clorox for its results. The question tonight — given the JP Morgan downgrade, the 5% one-month price decline to $96.60, and a short-interest count now running near a 30-day high — is whether the same dynamic holds when the Street is already positioned more skeptically than it was heading into either of those prints.
The ORTEX short score has climbed to 48.7, its highest of the past two weeks, after spending most of early April in the low 40s. What to watch: whether a clean beat re-triggers the pattern seen in the last two quarters, or whether the sheer volume of target cuts in recent weeks signals a more durable reset in expectations.
See the live data behind this article on ORTEX.
Open CLX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
